Updated use of aminoquinolines for the treatment of COVID 19
Main Article Content
Keywords
Aminoquinolines, COVID-19, Hydroxychloroquine, Chloroquine, Therapeutics, Coronavirus Infections
Abstract
Due to the current pandemic produced by the SARS‑CoV‑2, there has been a scientific race in order to find an appropriate treatment and prophylaxis for patients with COVID-19. Multiple studies in the literature have shown that chloroquine and hydroxychloroquine inhibits the virus in vitro. However the majority of the in vivo data comes from observational studies, some of these with severe flaws in their study design. It’s important to make conclusions based on the results of the randomized controlled trials that are underway.
References
1. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Research. 2020;30(3):269-71. doi:10.1038/s41422-020-0282-0
2. Wellems TE, Plowe CV. Chloroquine-resistant Malaria. J Infect Dis. 2001;184(6):770-6. doi:10.1086/322858
3. Devaux CA, Rolain J-M, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus:what to expect for COVID-19?Int J Antimicrob Agents. 2020;55(5):105938. doi:10.1016/j.ijantimicag.2020.105938
4. Jang C-H, Choi J-H, Byun M-S, Jue D-M. Chloroquine inhibits production of TNF-a, IL-1b and IL-6 from lipopolysaccharide-stimulated human monocytes/macrophages by different modes. Rheumatology. 2006;45(6):703-10. doi:10.1093/rheumatology/kei282
5. Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virology Journal. 2005;2(1):69. doi:10.1186/1743-422X-2-69
6. Boulware DR, Pullen MF, Bangdiwala AS, Pastick KA, Lofgren SM, Okafor EC, et al. A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. N Engl J Med. 2020;383(6):517-25. doi:10.1056/NEJMoa2016638
7. Mehra MR, Desai SS, Ruschitzka F, Patel AN. RETRACTED:Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19:a multinational registry analysis. Lancet. 2020;S0140-6736(20):3118-06. doi:10.1016/S0140-6736(20)31180-6
8. Joseph A. WHO resumes hydroxychloroquine study for Covid-19 [Internet]. STAT. [consultado el 9 de junio de 2020]. [aprox. 2 pantallas]. Dispo-nible en:https://www.statnews.com/2020/06/03/who-resuming-hydroxychloroquine-study-for-covid-19/
9. Davey M, Kirchgaessner S, Boseley S. Surgisphere:governments and WHO changed Covid-19 policy based on suspect data from tiny US company [Internet]. The Guardian. [Actualizado 3 Jun 2020;citado 9 Jun 2020]. [aprox. 4 pantallas]. Disponible en:https://www.theguardian.com/world/2020/jun/03/covid-19-surgisphere-who-world-health-organization-hydroxychloroquine
10. Mehra MR, Ruschitzka F, Patel AN. Retraction—Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19:a multinational registry analysis. Lancet. 2020;395(10240):1820, doi:10.1016/S0140-6736(20)31324-6
Article Sidebar
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors retain their copyright and grant the Revista Médica del IMSS the right of first publication. Articles are distributed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which allows sharing as long as the author and the original source are properly credited.